-
The PDC track is hot! Domestic and foreign pharmaceutical companies are competing for layout
Time of Update: 2023-02-01
Specifically, on December 22, 2022, Merck and PeptiDream entered into an agreement to discover and develop new PDCs based on PeptiDream's drug discovery and development platform technology PDPS (Peptide Discovery Platform System), and PeptiDream will receive an upfront payment and may receive a total of up to $2.
-
Qinghai adjusted the charging prices of 1163 medical service items
Time of Update: 2022-09-21
(End)Pharmaceutical enterprises On the 13th, the reporter learned from the press conference on the "Qinghai Decade" medical insurance work held by the Information Office of the Qinghai Provincial Government on the same day that in order to continue to promote the reform of centralized recruitment of pharmaceutical consumables, Qinghai Province completely cancelled the bonus of drugs and medical consumables in public medical institutions, and the burden of medical treatment for the people was further reduced.
-
Kanglong Chemical's performance has "greatly changed", and the domestic CXO industry may enter a bottleneck period of development
Time of Update: 2022-08-15
Driven by many factors such as overseas order transfer, strong domestic demand for innovative drug research and development, expansion of the pharmaceutical market, and government preferential policies, the growth rate of China's CXO market has exceeded that of the global market in the past five years .
-
Tu Pengfei/Zeng Kewu's team revealed the antitumor target of cucurbitacin B
Time of Update: 2022-08-15
Recently, Tu Pengfei / Zeng Kewu's team from the State Key Laboratory of Natural and Biomimetic Drugs, School of Pharmacy, Peking University published a study entitled "Allosteric regulation of IGF2BP1 as a novel strategy for the activation of tumor immune microenvironment" in the international academic journal ACS Central Science In this paper, the molecular target and mechanism of action of cucurbitacin B, the active ingredient of guar thorn in traditional Chinese medicine, have been elucidated in depth .
-
Ministry of Commerce promulgated "Regulations on the List of Unreliable Entities
Time of Update: 2022-06-20
List of unreliable entities List of unreliable entitiesList of unreliable entities Article 1 In order to safeguard national sovereignty, security, and development interests, maintain a fair and free international economic and trade order, and protect the legitimate rights and interests of Chinese enterprises, other organizations or individuals, in accordance with the "Foreign Trade Law of the People's Republic of China" and "National Security of the People's Republic of China" Law” and other relevant laws, formulate these regulations.
-
Fujian announces the third batch of medical insurance key monitoring drugs and the list of key drugs
Time of Update: 2022-03-09
24), with the approval of the Provincial Medical Insurance Bureau, the "Third Batch of Medical Insurance Key Monitoring Drugs List" and the "Third Batch of Medical Insurance Focused Drug List" to be announced .
-
China Condiment Association Group Standard "List of Spices for Condiment Industry
Time of Update: 2022-01-08
doc Group Standards Technical Committee of China Seasoning Association December 29, 2012 By the Chinese condiment made associations, groups and administered a standard "condiment industry with the spice list of" standard form for comments draft (see Annex 1), are to be publicized .
-
Keytruda leads the "leader gene" in the treatment of gastrointestinal tumors
Time of Update: 2021-08-09
KEYNOTE-811 Surprising Gastric CancerKEYNOTE-811 Surprising Gastric CancerOn May 5 this year, the US FDA accelerated the approval of drug K in combination with trastuzumab and fluoropyrimidine/platinum-based chemotherapy for the first-line treatment of patients with HER2-positive locally advanced unresectable or metastatic gastric or gastroesophageal junction adenocarcinoma The approval of the indication is based on the interim analysis results of a global multi-center, randomized controlled, double-blind phase III clinical study KEYNOTE-811 .
-
Guangdong Medical Insurance Bureau issued a document: Hospitals give priority to using domestic medical consumables
Time of Update: 2021-07-06
(Screenshot source: Guangdong Provincial Medical Insurance Bureau) It is reported that in December 2020, Guangdong Province issued the "Notice on the Implementation of the National Medical Security Administration's Opinions on the National Organization for the Centralized Procurement of Coronary Stents and the Use of Supporting Measures".
-
Astellas Fumaric acid glytinib tablets have been approved for the treatment of recurring or refractic acute myelin
Time of Update: 2021-03-08
- Accelerated approval after being included in the priority review and clinically urgent need for new drugs from abroad - Ginitinib is the first and currently the only FLT3 inhibitor approved by Chin
-
Heilongjiang demands to ensure the supply of medicines in short supply
Time of Update: 2021-02-21
Health Security Bureau of Heilongjiang Province recently issued a "notice on further doing a good job in the supply of shortage of drugs and price stability", calling for the strengthening of normal drug price supervision.
-
Anesthesia, psychotics, these special drugs production and sales within 7 days to report
Time of Update: 2021-02-05
The State Drug Administration issued the Notice on the Official Operation of the Information Reporting System on the Production and Circulation of Special Drugs, requiring pharmaceutical manufacturers of narcotic drugs, psychotic drugs and pharmaceutical-type easy-to-make chemicals to report them within 7 days of the occurrence of production and business activities.
-
3.2 billion market change? Fourth batch collection, Pfizer "exclusive three yuan
Time of Update: 2021-01-26
Pfizer, Cosmos, the world's largest pharmaceutical company, has been hit by a volume-buying policy that has made the future even more uncertain. According to the data combed by the author, each round
-
From next year, a large number of drugs will stop Medicare reimbursement
Time of Update: 2020-11-07
Chongqing Municipal Health Insurance Bureau on June 8 issued "on the gradual digestion of chongqing city to supplement the list of medical insurance Class B drugs", clearly the first year of digestion of drugs, from January 1, 2021 to stop medical insurance reimbursement.
-
HIV Infection Emergency Listed HIV-1 Protease Inhibitor Overview
Time of Update: 2020-09-28
the FDA currently lists 10 anti-HIV-1 protease inhibitors, including: Saquinavir (Saquinavir, SQV), Ritonavir (Litonavi, RTV), Indinavir ( Dinave, IDV), Nelfinavir (Nifinavir, NFV), Amprenavir (Ampnavir, APV), Fosamprenavir (Fosanawe, Fos-APV), Lopinavir (Lopinave, LPV), Atazanavir (Azanavi, ATV), Tipranavir (TPV) and Darunavir (Darunawe, DRV).
